



**Supplementary Figure 3. Association between pretreatment cfDNA concentration and clinicopathologic variables.** CfDNA concentration was measured in pretreatment plasma of patients with **A.** hormone receptor-positive HER2-negative (HR+HER2-) and **B.** triple-negative breast cancers (TNBC). P values were calculated using the Wilcoxon rank sum test.